Accessing COVID-19 mRNA Vaccines for Research: The Re-emergence of the Tragedy of the ‘Anticommons’
COVID-19 vaccine manufacturers refusing to share samples may be the latest example of the tragedy of the “anticommons” in biomedical research.
mRNA vaccines
-
Read more: Accessing COVID-19 mRNA Vaccines for Research: The Re-emergence of the Tragedy of the ‘Anticommons’ -
Read more: Why Do Differences in Clinical Trial Design Make It Hard to Compare COVID-19 Vaccines? Why Do Differences in Clinical Trial Design Make It Hard to Compare COVID-19 Vaccines?
Because of differences in how they were tested in clinical trials, it is difficult to make apples-to-apples comparisons for COVID-19 vaccines.
-
Read more: What’s the Difference Between Vaccine Approval (BLA) and Authorization (EUA)? What’s the Difference Between Vaccine Approval (BLA) and Authorization (EUA)?
A Biologics License Application, or BLA, is FDA’s standard “full approval” mechanism for biological products, including therapeutics and vaccines.
-
Read more: How Can Policymakers Overcome the Hurdles to Scaling up Antibody Manufacturing? How Can Policymakers Overcome the Hurdles to Scaling up Antibody Manufacturing?
The difficult manufacturing issues involved in the therapeutic antibody context, and what might be done to address them.
-
Read more: Why Aren’t Therapeutic Antibodies Being Used More to Treat COVID-19? Why Aren’t Therapeutic Antibodies Being Used More to Treat COVID-19?
The rapid development of therapeutic antibodies is a triumph of biomedical innovation. But they won’t help unless they make it to patients.
-
Read more: What Can Policymakers Learn from the Slow COVID-19 Vaccine Rollout? What Can Policymakers Learn from the Slow COVID-19 Vaccine Rollout?
In this post we explain what went wrong and how policymakers can correct course for COVID-19 and avoid such disasters in the future.
-
Read more: Can Schools Require the COVID-19 Vaccine? Education, Equity, and the Courts Can Schools Require the COVID-19 Vaccine? Education, Equity, and the Courts
Given the potential legal challenges policymakers may face, legislation to remedy the COVID-19 educational crisis must be carefully drafted.
-
Read more: How Can Policymakers Encourage COVID-19 Vaccine Trials for Children? How Can Policymakers Encourage COVID-19 Vaccine Trials for Children?
We explain why COVID-19 vaccines are only just starting to be tested in children and what policymakers can do to spur pediatric vaccine trials.
-
Read more: How are COVID-19 Vaccine Manufacturers Building Trust in the FDA’s Approval Process? How are COVID-19 Vaccine Manufacturers Building Trust in the FDA’s Approval Process?
Pharmaceutical companies are now also engaging the public themselves in an attempt to build trust in their products.
-
Read more: How Does Moderna’s COVID-19 Vaccine Work, and Who Is Funding Its Development? How Does Moderna’s COVID-19 Vaccine Work, and Who Is Funding Its Development?
Moderna’s vaccine works using a completely novel mechanism, unlike any other vaccine currently approved anywhere in the world.
